EP0693552A2 - Analytical element, composition and method using modified apo-horseradish peroxidase - Google Patents
Analytical element, composition and method using modified apo-horseradish peroxidase Download PDFInfo
- Publication number
- EP0693552A2 EP0693552A2 EP95305007A EP95305007A EP0693552A2 EP 0693552 A2 EP0693552 A2 EP 0693552A2 EP 95305007 A EP95305007 A EP 95305007A EP 95305007 A EP95305007 A EP 95305007A EP 0693552 A2 EP0693552 A2 EP 0693552A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- peroxidase
- labeled
- specific binding
- apo
- immunoreactant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108040007629 peroxidase activity proteins Proteins 0.000 title claims description 112
- 238000000034 method Methods 0.000 title claims description 44
- 102000003992 Peroxidases Human genes 0.000 title claims description 26
- 239000000203 mixture Substances 0.000 title claims description 15
- -1 histidine amino acids Chemical class 0.000 claims abstract description 31
- 238000003556 assay Methods 0.000 claims abstract description 30
- 102000001554 Hemoglobins Human genes 0.000 claims abstract description 16
- 108010054147 Hemoglobins Proteins 0.000 claims abstract description 16
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 14
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 14
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims abstract description 10
- 210000002966 serum Anatomy 0.000 claims abstract description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 58
- 230000009870 specific binding Effects 0.000 claims description 51
- 239000003446 ligand Substances 0.000 claims description 44
- 238000003892 spreading Methods 0.000 claims description 34
- 230000007480 spreading Effects 0.000 claims description 34
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 18
- 239000012491 analyte Substances 0.000 claims description 17
- 239000012530 fluid Substances 0.000 claims description 17
- 238000003018 immunoassay Methods 0.000 claims description 17
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical class C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims description 15
- 229960005156 digoxin Drugs 0.000 claims description 13
- 229960002036 phenytoin Drugs 0.000 claims description 13
- 239000000758 substrate Substances 0.000 claims description 13
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims description 12
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims description 12
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims description 12
- 239000000872 buffer Substances 0.000 claims description 9
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 8
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 6
- BRDWIEOJOWJCLU-LTGWCKQJSA-N GS-441524 Chemical compound C=1C=C2C(N)=NC=NN2C=1[C@]1(C#N)O[C@H](CO)[C@@H](O)[C@H]1O BRDWIEOJOWJCLU-LTGWCKQJSA-N 0.000 claims description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 5
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 5
- 229960000623 carbamazepine Drugs 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 5
- 229940088597 hormone Drugs 0.000 claims description 5
- 239000005556 hormone Substances 0.000 claims description 5
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 claims description 5
- 229960002695 phenobarbital Drugs 0.000 claims description 5
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 4
- 102100032752 C-reactive protein Human genes 0.000 claims description 4
- KKCIOUWDFWQUBT-AWEZNQCLSA-N L-thyronine Chemical class C1=CC(C[C@H](N)C(O)=O)=CC=C1OC1=CC=C(O)C=C1 KKCIOUWDFWQUBT-AWEZNQCLSA-N 0.000 claims description 4
- 230000009137 competitive binding Effects 0.000 claims description 4
- 239000002207 metabolite Substances 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 102000011022 Chorionic Gonadotropin Human genes 0.000 claims description 3
- 108010062540 Chorionic Gonadotropin Proteins 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- 239000013522 chelant Substances 0.000 claims description 3
- 229940084986 human chorionic gonadotropin Drugs 0.000 claims description 3
- 229960000707 tobramycin Drugs 0.000 claims description 3
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims description 3
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims description 3
- 210000002381 plasma Anatomy 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 102000011923 Thyrotropin Human genes 0.000 claims 2
- 108010061174 Thyrotropin Proteins 0.000 claims 2
- 238000012360 testing method Methods 0.000 abstract description 21
- 238000004458 analytical method Methods 0.000 abstract description 5
- 230000000903 blocking effect Effects 0.000 abstract description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract description 4
- 230000003197 catalytic effect Effects 0.000 abstract 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 87
- 239000010410 layer Substances 0.000 description 55
- 239000000243 solution Substances 0.000 description 19
- 239000000463 material Substances 0.000 description 16
- 239000000523 sample Substances 0.000 description 13
- 238000000576 coating method Methods 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- 239000000975 dye Substances 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 5
- 238000000159 protein binding assay Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 238000009739 binding Methods 0.000 description 4
- 239000012954 diazonium Substances 0.000 description 4
- 238000007756 gravure coating Methods 0.000 description 4
- 125000002883 imidazolyl group Chemical group 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 125000003831 tetrazolyl group Chemical group 0.000 description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 108090001008 Avidin Proteins 0.000 description 3
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 239000013060 biological fluid Substances 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 239000008199 coating composition Substances 0.000 description 3
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 3
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 3
- 239000002523 lectin Substances 0.000 description 3
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002736 nonionic surfactant Substances 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 150000002978 peroxides Chemical class 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 229940034208 thyroxine Drugs 0.000 description 3
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002152 alkylating effect Effects 0.000 description 2
- 150000001448 anilines Chemical class 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 2
- 229940106681 chloroacetic acid Drugs 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical compound [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 2
- 239000012992 electron transfer agent Substances 0.000 description 2
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 2
- 230000005281 excited state Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229960000278 theophylline Drugs 0.000 description 2
- SIFCHNIAAPMMKG-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) acetate Chemical compound CC(=O)ON1C(=O)CCC1=O SIFCHNIAAPMMKG-UHFFFAOYSA-N 0.000 description 1
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
- PQUXFUBNSYCQAL-UHFFFAOYSA-N 1-(2,3-difluorophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(F)=C1F PQUXFUBNSYCQAL-UHFFFAOYSA-N 0.000 description 1
- STBYRSZXHDPASK-UHFFFAOYSA-N 1-(chloromethyl)-2-methylnaphthalene Chemical compound C1=CC=CC2=C(CCl)C(C)=CC=C21 STBYRSZXHDPASK-UHFFFAOYSA-N 0.000 description 1
- HLQZCRVEEQKNMS-UHFFFAOYSA-N 1-(chloromethyl)-4-phenylbenzene Chemical group C1=CC(CCl)=CC=C1C1=CC=CC=C1 HLQZCRVEEQKNMS-UHFFFAOYSA-N 0.000 description 1
- XMWGTKZEDLCVIG-UHFFFAOYSA-N 1-(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1 XMWGTKZEDLCVIG-UHFFFAOYSA-N 0.000 description 1
- IVYDZBRMECSWSH-UHFFFAOYSA-N 1-(hydrazinecarbonyl)naphthalene-2-carboxylic acid Chemical class C1=CC=C2C(C(=O)NN)=C(C(O)=O)C=CC2=C1 IVYDZBRMECSWSH-UHFFFAOYSA-N 0.000 description 1
- CZQIJQFTRGDODI-UHFFFAOYSA-N 1-bromo-4-isocyanatobenzene Chemical compound BrC1=CC=C(N=C=O)C=C1 CZQIJQFTRGDODI-UHFFFAOYSA-N 0.000 description 1
- KGLPWQKSKUVKMJ-UHFFFAOYSA-N 2,3-dihydrophthalazine-1,4-dione Chemical group C1=CC=C2C(=O)NNC(=O)C2=C1 KGLPWQKSKUVKMJ-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- VJEZYZLITKUTFH-UHFFFAOYSA-N 2-(hydrazinecarbonyl)benzoic acid Chemical class NNC(=O)C1=CC=CC=C1C(O)=O VJEZYZLITKUTFH-UHFFFAOYSA-N 0.000 description 1
- KLHVKSXCTICWSO-UHFFFAOYSA-N 2-(hydrazinecarbonyl)coronene-1-carboxylic acid Chemical class C1(=C(C2=CC=C3C=CC4=CC=C5C=CC6=CC=C1C1=C6C5=C4C3=C21)C(=O)O)C(=O)NN KLHVKSXCTICWSO-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- MWRHOPMYLRWJGK-UHFFFAOYSA-N 3-(hydrazinecarbonyl)anthracene-2-carboxylic acid Chemical class C1=CC=C2C=C(C=C(C(C(=O)NN)=C3)C(O)=O)C3=CC2=C1 MWRHOPMYLRWJGK-UHFFFAOYSA-N 0.000 description 1
- KTJRGPZVSKWRTJ-UHFFFAOYSA-N 3-chloro-1-phenylpropan-1-one Chemical compound ClCCC(=O)C1=CC=CC=C1 KTJRGPZVSKWRTJ-UHFFFAOYSA-N 0.000 description 1
- JQDXZJYAUSVHDH-UHFFFAOYSA-N 3-chloropropanamide Chemical compound NC(=O)CCCl JQDXZJYAUSVHDH-UHFFFAOYSA-N 0.000 description 1
- QEYMMOKECZBKAC-UHFFFAOYSA-N 3-chloropropanoic acid Chemical compound OC(=O)CCCl QEYMMOKECZBKAC-UHFFFAOYSA-N 0.000 description 1
- OITNBJHJJGMFBN-UHFFFAOYSA-N 4-(chloromethyl)benzoic acid Chemical compound OC(=O)C1=CC=C(CCl)C=C1 OITNBJHJJGMFBN-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 241000606750 Actinobacillus Species 0.000 description 1
- 108010006591 Apoenzymes Proteins 0.000 description 1
- 108010083590 Apoproteins Proteins 0.000 description 1
- 102000006410 Apoproteins Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- FLVMDDSFLMTEMB-UHFFFAOYSA-N C=1(C(=CC=C2C3=CC=CC=C3CC=12)C(=O)O)C(=O)NN Chemical class C=1(C(=CC=C2C3=CC=CC=C3CC=12)C(=O)O)C(=O)NN FLVMDDSFLMTEMB-UHFFFAOYSA-N 0.000 description 1
- 241000498849 Chlamydiales Species 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 241001136705 Glechoma hederacea Species 0.000 description 1
- CTKINSOISVBQLD-UHFFFAOYSA-N Glycidol Chemical compound OCC1CO1 CTKINSOISVBQLD-UHFFFAOYSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- OWXMKDGYPWMGEB-UHFFFAOYSA-N HEPPS Chemical compound OCCN1CCN(CCCS(O)(=O)=O)CC1 OWXMKDGYPWMGEB-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700020962 Peroxidase Proteins 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
- 241000605894 Porphyromonas Species 0.000 description 1
- 241000605861 Prevotella Species 0.000 description 1
- 102400000096 Substance P Human genes 0.000 description 1
- 101800003906 Substance P Proteins 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 102000004903 Troponin Human genes 0.000 description 1
- 108090001027 Troponin Proteins 0.000 description 1
- FHKPLLOSJHHKNU-INIZCTEOSA-N [(3S)-3-[8-(1-ethyl-5-methylpyrazol-4-yl)-9-methylpurin-6-yl]oxypyrrolidin-1-yl]-(oxan-4-yl)methanone Chemical compound C(C)N1N=CC(=C1C)C=1N(C2=NC=NC(=C2N=1)O[C@@H]1CN(CC1)C(=O)C1CCOCC1)C FHKPLLOSJHHKNU-INIZCTEOSA-N 0.000 description 1
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 125000005100 aryl amino carbonyl group Chemical group 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000012993 chemical processing Methods 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 239000013581 critical reagent Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 150000001989 diazonium salts Chemical class 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- JOXWSDNHLSQKCC-UHFFFAOYSA-N ethenesulfonamide Chemical compound NS(=O)(=O)C=C JOXWSDNHLSQKCC-UHFFFAOYSA-N 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000013198 immunometric assay Methods 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 235000013980 iron oxide Nutrition 0.000 description 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 239000012035 limiting reagent Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- METFEORCOGUCCZ-UHFFFAOYSA-N n-(3,5-dichloro-4-hydroxyphenyl)acetamide Chemical compound CC(=O)NC1=CC(Cl)=C(O)C(Cl)=C1 METFEORCOGUCCZ-UHFFFAOYSA-N 0.000 description 1
- JULKJDRBSRRBHT-UHFFFAOYSA-N n-(3-chloro-4-hydroxyphenyl)acetamide Chemical compound CC(=O)NC1=CC=C(O)C(Cl)=C1 JULKJDRBSRRBHT-UHFFFAOYSA-N 0.000 description 1
- HNHVTXYLRVGMHD-UHFFFAOYSA-N n-butyl isocyanate Chemical compound CCCCN=C=O HNHVTXYLRVGMHD-UHFFFAOYSA-N 0.000 description 1
- NSNPSJGHTQIXDO-UHFFFAOYSA-N naphthalene-1-carbonyl chloride Chemical compound C1=CC=C2C(C(=O)Cl)=CC=CC2=C1 NSNPSJGHTQIXDO-UHFFFAOYSA-N 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 230000003617 peroxidasic effect Effects 0.000 description 1
- KIZSMODMWVZSNT-UHFFFAOYSA-N perylene-1,2-dicarboxylic acid Chemical compound C1=CC(C2=C(C(C(=O)O)=CC=3C2=C2C=CC=3)C(O)=O)=C3C2=CC=CC3=C1 KIZSMODMWVZSNT-UHFFFAOYSA-N 0.000 description 1
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000007430 reference method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 229940047670 sodium acrylate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Substances [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- SONHXMAHPHADTF-UHFFFAOYSA-M sodium;2-methylprop-2-enoate Chemical compound [Na+].CC(=C)C([O-])=O SONHXMAHPHADTF-UHFFFAOYSA-M 0.000 description 1
- BWYYYTVSBPRQCN-UHFFFAOYSA-M sodium;ethenesulfonate Chemical compound [Na+].[O-]S(=O)(=O)C=C BWYYYTVSBPRQCN-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 229940035722 triiodothyronine Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
- C12Q1/28—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving peroxidase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/962—Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/968—High energy substrates, e.g. fluorescent, chemiluminescent, radioactive
Definitions
- This invention relates to analytical elements, compositions and methods for using them to detect an analyte using peroxidase or a peroxidase-labeled specific binding reagent.
- it relates to the reduction of hemoglobin bias in the detection of such analytes as well as the reduction of bias from other known protein interferents.
- specific binding assays can provide a qualitative or quantitative determination (or both) of the presence or absence (or quantity) of an analyte of interest.
- assay known as a "competitive binding immunoassay”
- a labeled analog of the ligand to be determined is placed in competition with a fixed amount of an appropriate antibody which can react with both the ligand and the ligand analog.
- the label on the analog can be appropriately detected in its “free” or complexed (that is, reacted) form. Signal level then will tell the user how much ligand is in the sample being tested.
- the ligand is contacted with two or more receptor molecules which bind to the ligand at different epitopic sites.
- One receptor is typically appropriately labeled and the other is either immobilized on a solid substrate, or is capable of being immobilized thereon.
- the amount of ligand is directly proportional to the amount of bound complex among the ligand and the two receptors.
- Immunoassays have been traditionally carried out in solution or in test devices where fluids are removed in some fashion from the reagents participating in the assay. Dry analytical elements and their use for immunoassays are described in numerous publications, including US-A-4,258,001 (Pierce et al), US-A-4,670,381 (Frickey et al), WO 82/2601 (published August 5, 1992), EP-A-0 051 183 (published May 12, 1982) and EP-A-0 066 648 (published December 15, 1982).
- results may be altered by the presence of materials in test samples that affect the activity of the enzyme.
- These interfering effects can be overcome by including in the assay system, materials that block the effect of the interferents.
- WO 86/07462 (published December 18, 1986) describes the use of certain modified forms of peroxidase to reduce the effect of interferents in solution assays. Those forms include apo-horseradish peroxidase, carboxymethylated apo-horseradish peroxidase and acidic forms of horseradish peroxidase.
- the present invention also provides a method for the determination of an analyte comprising:
- composition of this invention comprises:
- the present invention provides an accurate method for detecting an analyte using a peroxidase or a peroxidase-labeled specific binding reagent.
- the invention is particularly advantageous using a dry analytical element in the assay. The effects of known interferents to peroxidase labels are minimized as expected, and bias from the presence of hemoglobin is unexpectedly avoided.
- Blocking can be accomplished by substitution on at least one of the nitrogen atoms of the histidine imidazolyl groups as described in more detail below.
- the modified apo-peroxidase remains effective to reduce the interfering effects by other common serum protein interferents.
- the art teaches that unmodified apo-peroxidase should be equally useful as modified forms of the enzyme, such as carboxymethylated apo-peroxidase, to remove interferents in solution assays.
- the unmodified apo-peroxidase causes additional bias in the assay resulting from the presence of hemoglobin.
- the present invention addresses this problem and provides a further improvement.
- FIG. 1 is a graphical representation of assay data (bias vs. coating levels) obtained using various analytical elements from three patient samples, as described in detail in Example 3 below.
- the present invention can be practiced to advantage in any analytical method designed to generate a colorimetric, fluorometric or chemiluminescent signal in response to the presence of peroxidase.
- Such assays can involve the detection of an organic or inorganic peroxide (such as hydrogen peroxide) or peroxidase (in its free form), or the detection of a non-immunological analyte other than peroxidase using reaction schemes which involve the reaction of peroxidase.
- the invention is directed to the practice of specific binding assays.
- the assay can be qualitative, quantitative or semi-quantitative to detect one or more of a wide variety of analytes in aqueous liquids, such as human and animal biological fluids, waste fluids, foods, environmental effluent, chemical processing liquids and other specimens readily apparent to one skilled in the art.
- Biological fluids such as human or animal serum, plasma or urine are preferably assayed with this invention.
- Hydrogen peroxide (or another peroxide) can be determined with this invention as well as analytes capable of producing peroxide. That is, the analyte may be capable of participating in one or more reactions which produce hydrogen peroxide which then is detected using suitable signal-producing reagents and a peroxidase.
- the present invention is particularly advantageous in assays where the peroxidase is used in a rate limiting fashion.
- assays are specific binding assays wherein the peroxidase is used as a label on one of the immunoreactants needed to detect a specific binding ligand.
- a skilled clinical chemist would readily understand that there may be assays for metabolites, enzymes or other non-immunoreactive analytes wherein peroxidase also is used in a rate limiting fashion. Therefore, the present invention is not intended to be limited to specific binding assays.
- Analytical compositions of this invention which are useful in solution assays can include a peroxidase or a peroxidase-labeled specific binding reagent, a modified apo-peroxidase (defined below), one or more reagents for producing a signal (defined below), and optionally, a phenol or aniline "coreagent" for those signal-producing reagents.
- Coreagents which can be used in this manner include compounds which are variously known as "electron transfer agents” for producing dye signals, such as the phenols and anilines described for example, in US-A-4,828,983 (McClune), and as “enhancers” for producing chemiluminescent signals as described, for example in US-A-4,729,950 (Kricka et al) and US-A-4,598,044 (Kricka et al). All three of these patents are incorporated herein by reference. Other useful coreagents are described in EP-A-0 603 954.
- Three preferred coreagents are 4'-hydroxyacetanilide, 3'-chloro-4'-hydroxyacetanilide and 3',5'-dichloro-4'-hydroxyacetanilide.
- the peroxidase or peroxidase-labeled specific binding reagent, and signal-generating reagents can be present in any suitable concentration which would be readily apparent to the skilled artisan.
- the modified apo-peroxidase is generally present in an amount of from about 10 ⁇ 9 to about 10 ⁇ 3, with from about 10 ⁇ 7 to about 10 ⁇ 5 being preferred.
- the phenol or aniline coreagent can be present in an amount of from about 0.001 to about 150 mmolar, with from about 0.01 to about 50 mmolar being preferred. It would be readily apparent to a skilled worker as to how adjustments of the various amounts should be made in a given composition for a given analyte.
- the present invention is directed to an element and method for detecting target specific binding ligands (identified as ligands hereinafter) for which receptor molecules are available or manufacturable.
- ligand-receptor complexes that is, a reaction product of ligand and corresponding receptor
- ligand-receptor complexes include, but are not limited to, antibody-antigen, antibody-hapten, avidin-biotin, sugar-lectin, gelatin-fibronectin and Protein A-IgG complexes.
- complementary nucleic acids that is, hybridized products of complementary strands also are considered ligand-receptor complexes.
- Ligands include, but are not limited to, peptides, polypeptides, proteins (including enzymes, antibodies, antigenic proteins, glycoproteins, lipoproteins and avidin), hormones (such as thyroxine, triiodothyronine, human chorionic gonadotropin, estrogen, ACTH and substance P), vitamins, human immune system modulators (such as interleukin-6), steroids, carbohydrates (such as polysaccharides), glycolipids, drugs (such as digoxin, phenytoin, phenobarbital, morphine, carbamazepine and theophylline), antibiotics (such as gentimicin), components of cells and viruses (such as Streptococcal species, herpes viruses, Gonococcal species, Chlamydial species, retroviruses, influenza viruses, Prevotella species, Porphyromonas species, Actinobacillus species and Mycobacterium species), nucleic acids (including single- and double-stranded oligonucle
- this invention is particularly advantageous for using dry analytical elements to detect analytes wherein the peroxidase-labeled specific binding reagent is present in the element in rate limiting amounts.
- analytes which can be so determined in solution or dry formats using peroxidase as a rate limiting reactant include, but are not limited to, diphenylhydantoin (or phenytoin), carbamazepine, phenobarbital, C-reactive protein, digoxin, a thyronine derivative (such as thyroxine and triiodothrionine), morphine, theophylline, gentamicin, vancomicin, tobramicin, TSH, hCG, various proteins (such as IgM, IgG, IgE and IgA proteins), creatine kinase-MB, troponins T and I, and apoproteins A, A1 and B.
- diphenylhydantoin or phenytoin
- carbamazepine or phenobarbital
- C-reactive protein digoxin
- a thyronine derivative such as thyroxine and triiod
- the term "antibody” includes whole immunoglobulin molecules having a single specificity as is conventional in the art.
- the term is intended to include chemically prepared fragments [such as Fab, F(ab) ', F(ab)2 fragments] of such molecules and genetically prepared equivalents thereof (such as "single chain antibody fragments” or ScFv fragments).
- the antibodies can be monoclonal or polyclonal.
- the present invention is preferably carried out using an analytical element comprising a porous spreading layer (usually a coated layer) which has a suitable porosity for accommodating a test sample, diluted or undiluted.
- a porous spreading layer usually a coated layer
- the porous spreading layer is isotropically porous, meaning that it is equally porous in every dimension so that fluids spread uniformly in every dimension, as provided by interconnected fibers, particles and other components of the layer.
- Materials useful for preparing such elements are well known.
- the porous layers can be composed of cellulosic, glass or polymeric fibers, polymeric or inorganic particulate materials or a combination of such materials.
- the element can include additional layers besides the porous spreading layers as long as all the layers are in fluid contact, meaning that fluids can move readily from one layer to another, even if such reagents do not readily move from one layer to another.
- additional layers are usually coated layers of various binder materials and one or more reagents useful in the assay, and include what are known in the art as subbing, reagent, registration and radiation blocking layers.
- Materials useful as binders in such layers are well known as described in the patents noted in the preceding paragraph, and preferably include gelatin (hardened or unhardened), hydrophilic acrylamide and vinylpyrrolidone polymers.
- Some layers may be water-insoluble while others are water-soluble or water-swellable so they dissolve or swell during an assay. It also is likely that some layers blend together during coating so that horizontal zones are formed in a single dried layer from different coating formulations.
- the layers of the element can be self-supporting, but preferably they are disposed on a suitable dimensionally stable, nonporous, chemically inert support.
- Useful support materials include polymeric films, metal foils, paper and other materials well known in the art.
- a transparent polyester support is preferred.
- the peroxidase or peroxidase-labeled specific binding reagent used in the practice of the present invention is included in one or more layers of the element. This reagent is capable of binding to either the specific binding ligand of interest or its corresponding receptor.
- the labeled reagent is usually a labeled analog of the specific binding ligand (such as labeled haptenic derivatives of the ligand).
- the labeled immunoreactant can be a labeled receptor for the ligand, or it can be a labeled molecule (such as a labeled anti-antibody) which binds to the receptor (such as an antibody).
- Labeled specific binding reagents can be prepared using any of a number of known procedures, and many of such reagents are commercially available from a number of sources. Preparatory procedures include those described by Yoshitake et al Eur.J.Biochem. 101 , 395, 1979 and in US-A-5,106,732 (Kondo et al).
- peroxidase in this application is meant any peroxidative substance (enzymatic or otherwise) which catalyzes the oxidation of a substrate, such as a leuco dye, in the presence of hydrogen peroxide or other oxidant to produce an appropriate signal.
- a substrate such as a leuco dye
- Microbial, fungal or plant peroxidases are preferred with horseradish peroxidase being most preferred.
- the amount of a peroxidase-labeled specific binding reagent in an element of this invention can vary widely due to the amount of the other components used in the reaction and the suspected amount of analyte in the test sample. Generally, the amount present in the element is at least about 2 ⁇ g/m, with from about 4 to about 25 ⁇ g/m being preferred.
- the peroxidase-labeled specific binding reagent useful in this invention is preferably a peroxidase-labeled hapten derivative of the ligand or a peroxidase-labeled antibody.
- a conjugate of avidin or another specific binding compound with peroxidase also can be used in the practice of this invention.
- the label is on a hapten, for example, it can be a peroxidase-labeled drug, hormone, protein, metabolite, chelate or haptenic derivative of any of these.
- Such materials include, but are not limited to, peroxidase-labeled haptenic derivatives of digoxin, diphenylhydantoin, phenobarbital, C-reactive protein, a thyronine derivative such as thyroxine, carbamazepine or another analyte described above.
- a critical reagent used in the practice of this invention is a modified apo-peroxidase.
- These proteins have been modified by blocking the imidazolyl groups in the histidine amino acid molecules in the protein amino acid chain.
- the imidazolyl groups are blocked in at least one of the nitrogen atoms of the ring by substitution with any alkylating, condensation or addition reagent which sufficiently disrupts the stereo configuration of the histidine amino acids to prevent restoration of the peroxidase activity in the apo-peroxidase molecule, but does not alter the specific immunicity of the protein.
- the nitrogen atoms are blocked by the covalent attachment of an alkyl, aryl, alkanoyl, aroyl, alkoxycarbonyl, aryloxycarbonyl, alkylaminocarbonyl, or arylaminocarbonyl group thereto with an appropriate modifying addition, condensation or alkylating reagent.
- Such useful modifying addition reagents include active halogen alkylating agents of any type such as:
- modifying reagents include anhydrides (such as acetic anhydride, phthalic anhydride, diethyl pyrocarbonate and succinic anhydride), active esters (such as N-acetoxysuccinimide, N-proprionyloxysuccinimide and others as described in GB 2,064,800A), vinylsulfonyl and vinylcarbonyl group-containing compounds (such as vinylsulfonamide, sodium vinylsulfonate, sodium acrylate, sodium methacrylate, ethyl acrylate and others readily apparent to one skilled in the art), isocyanates (such as butyl isocyanate, p -bromophenyl isocyanate and phenyl isocyanate), aldehydes (such as benzaldehyde, acetaldehyde and propionaldehyde), and epoxides (such as glycidol).
- anhydrides such as acetic anhydride, phthalic
- An alternative and preferred technique comprises carboxyalkylating the apo-peroxidase using a suitable reagent such as iodoacetic acid, chloroacetic acid or bromoacetic acid. Details regarding such a technique are provided by Gurd in Methods in Enzymology , 11 , pages 532-541 (1967).
- the apo-peroxidase can be a carboxyalkylated derivative (that is, having carboxyalkylated histidine amino acids), as described below in Preparation 2 prior to the examples.
- the modified apo-peroxidase is present in the element of this invention in an amount of from about 0.1 to about 100 mg/m, and preferably at a coverage of from about 0.5 to about 20 mg/m. A preferred coverage is shown in the examples below.
- Peroxidase or a peroxidase-labeled specific binding reagent, and the modified apo-peroxidase are, independently, in the same or different layers of the element of this invention. Moreover, they can be independently in the porous spreading layer or in any additional layer of the element or in independent zones of a single layer (such as the porous spreading layer).
- a multilayer analytical element for the determination of a specific binding ligand of interest comprises a nonporous support having thereon, in fluid contact: a first reagent or buffer layer, a receptor layer comprising an unlabeled immunoreactant which specifically binds to either the specific binding ligand of interest or a receptor therefor, a porous spreading layer containing a reagent which provides a colorimetric or chemiluminescent signal in the presence of hydrogen peroxide and a peroxidase, and contiguous to the porous spreading layer, a second reagent layer containing: a peroxidase-labeled immunoreactant which specifically binds to either the specific binding ligand of interest or a receptor therefor, and a modified apo-horseradish peroxidase as defined above.
- a multilayer analytical element for the determination of a specific binding ligand of interest comprises a nonporous support having thereon, in fluid contact: a first reagent or buffer layer, and a porous spreading layer containing a reagent which provides a colorimetric or chemiluminescent signal in the presence of hydrogen peroxide and a peroxidase, the porous spreading layer having multiple zones, including a first zone containing an unlabeled immunoreactant which specifically binds to either the specific binding ligand of interest or a receptor therefor, and a second zone containing a peroxidase-labeled immunoreactant which specifically binds to either the specific binding ligand of interest or a receptor therefor, and a modified apo-horseradish peroxidase as defined above.
- the zones of the porous spreading layer can be horizontal or vertical regions of the layer. More preferably, they are horizontal zones created by separate coatings applied before or after coating application of the porous spreading layer components.
- the separate coatings may dissolve into the porous spreading layer forming a single dried layer with multiple zones.
- gravure coating technology is described in more detail in EP-A-0 517 338.
- the element is similar to the preferred element but the unlabeled immunoreactant, peroxidase-labeled immunoreactant and modified apo-horseradish peroxidase are distributed throughout the porous spreading layer.
- the element of this invention also can contain an unlabeled immunoreactant which is capable of specifically reacting with either the specific binding ligand of interest or its receptor.
- this immunoreactant is generally a receptor (such as an antibody) to the ligand.
- the unlabeled immunoreactant can be receptor for the ligand, or a binding molecule reactive with the receptor (such as an anti-antibody).
- the immunoreactant is an antibody specific to the ligand.
- the unlabeled immunoreactant and peroxidase-labeled immunoreactant are generally kept separated in some fashion in the element until the assay has begun. They may be separated by locating them in different layers of the element, or they may be in the same layer, but one component is encapsulated with a material that releases the component when the assay is begun, or they are can be located in separate zones of the same layer.
- the unlabeled immunoreactants be immobilized on suitable particles that are dispersed throughout a layer of the element.
- suitable particles can be composed of any suitable material including, but not limited to, glass, iron oxides, ceramics, organic synthetic or naturally occurring polymers, and have an average particle size of from about 0.01 to about 10 ⁇ m.
- the particles are prepared from synthetic polymers and have suitable surface groups for adsorption or covalent attachment of the immunoreactant molecules.
- Particularly useful polymeric particles are those prepared from ethylenically unsaturated polymerizable monomers having reactive carboxy, 2-substituted ethylsulfonyl or vinylsulfonyl groups as described in the patents noted in the preceding paragraph.
- peroxidase as the label in the method of this invention, there is a need to bring the peroxidase-labeled immunoreactant into contact with hydrogen peroxide or a similar oxidant and the appropriate reagents to produce a colorimetric or chemiluminescent signal.
- Useful reagents for providing a colorimetric signal include, but are not limited to, imidazole or triarylmethane leuco dyes, such as those described in US-A-4,089,747 (Bruschi) and references noted therein, US-A-4,670,385 (Babb et al), EP-A-0 122 641 (published October 24, 1984) and Japanese Patent Publication 58(1983)-045557.
- triarylimidazole leuco dyes of the Bruschi patent noted above, incorporated herein by reference, are preferred in the practice of this invention. Such leuco dyes are either commercially available or readily prepared using known procedures and starting materials.
- Diazonium and tetrazolium salts also are useful as long as they can provide a chromophore in the presence of peroxidase and an oxidant.
- a diazonium salt is generally an organic salt of a compound having a diazonium radical.
- Tetrazolium salts are organic salts in which the organic portion contains one or two tetrazole rings, generally having aryl substituents, at various positions.
- Chemiluminescent signals can be generated using a variety of known reagents.
- a preferred chemiluminescent signal generating reagent is a 2,3-dihydro-1,4-phthalazinedione derivative (identified herein as "DPD"). Any free or conjugated DPD that can be converted to an excited state in a chemiluminescent reaction and when returned to a non-excited state, emits light, is useful in the practice of this invention.
- DPD 2,3-dihydro-1,4-phthalazinedione derivative
- Such compounds are generally known as "luminol type hydrazides" and include phthalic hydrazides, naphthalene-1,2-dicarboxylic acid hydrazides, anthracene-2,3-dicarboxylic acid hydrazides, phenathrene-1,2-dicarboxylic acid hydrazides, fluorene-1,2-dicarboxylic acid hydrazides, benzo[g,h,i]perylene-1,2-dicarboxylic acid hydrazides, coronene-1,2-dicarboxylic acid hydrazides, and others readily apparent to one skilled in the art.
- Luminol is a preferred chemiluminescent signal generating reagent.
- Various phenols and anilines are used as enhancers with DPD compounds.
- the elements of this invention also can include a variety of addenda which are common to such elements to aid in manufacture, fluid spreading, absorbance of unwanted radiation and receptor stability.
- the element can be prepared using conventional coating procedures and equipment which are described in considerable art (including gravure, curtain, hopper and other coating techniques).
- the elements can be configured in a variety of forms and shapes, including elongated tapes of any desired width, sheets, slides or chips.
- the method of this invention can be manual or automated using appropriate analytical equipment and procedures.
- the method includes contacting the reagents in the element by spotting a test sample (for example, 1 to 200 ⁇ l) on the porous spreading layer.
- the movement of fluid within the element effectively mixes the reagents for the reactions to take place.
- the element is exposed to any condition, such as incubation, heating or another procedure, that may be desirable to quicken or otherwise facilitate the reactions in the element (as well as any specific binding complexes in immunoassays).
- a suitable signal for a quantitative result can be obtained without effective separation of the reacted (bound) and unreacted (unbound) forms of the peroxidase-labeled immunoreactant.
- the forms be separated within a zone of the element, as is typical in what are known as heterogeneous immunoassays.
- a signal can be evaluated in a defined region of the zone.
- a substrate solution for example 5 to 200 ⁇ l
- This solution may contain a substrate for the peroxidase or other signal producing reagents, or merely be a buffered wash solution.
- the substrate solution preferably contains a phenolic signal enhancer or electron transfer agent, many of which are known in the art.
- a preferred compound is 4'-hydroxyacetanilide.
- a modified apo-horseradish peroxidase was prepared by dissolving apo-horseradish peroxidase (1.1 g) in water (7 ml), diethyl pyrocarbonate (0.94 g) was added with stirring, and the resulting mixture was incubated with mixing at 24°C for 2 hours. Incubation was continued, with stirring, at 4°C for 18 additional hours.
- the resulting product mixture (21.5 ml) was dialyzed against two changes of phosphate buffer (3 liters, 10 mmolar, pH 7).
- the dialyzed mixture contained an apo-horseradish peroxidase (40 mg/ml) having ethoxycarbonyl groups on the imidazolyl groups of the histidine amino acids.
- An alternative modified apo-horseradish peroxidase was prepared by adding apo-horseradish peroxidase (3%) to a buffered solution of iodoacetic acid (3%, pH 5.5), and mixed at 24°C for 24 hours. The resulting product solution was dialyzed against 2 changes of water (3 liters) at 24°C for 24 hours. Analysis of the dialyzed mixture confirmed the presence of apo-horseradish peroxidase having imidazolyl groups substituted with carboxymethyl groups at a yield of about 85%.
- the peroxidase-labeled digoxin analog used in the elements was prepared by the procedures and from reagents described in EP-A-0 468 590 and EP-A-0 468 591.
- a water-soluble conjugate of a diphenylhydantoin hapten and amine-enriched horseradish peroxidase was prepared as follows. This preparation is representative only. Alternative preparative methods also exist.
- the hapten, 5,5-diphenyl-3- ⁇ 4-[4-(3-succinimidoxycarbonylpropionyl)-1-piperazinylcarbonyl]butyl ⁇ -2,4-imidazolidinedione, was prepared by procedures described in EP-A-0 517 327 (published May 5, 1993). It is identified as "HD-2" in that publication. Amine-enriched horseradish peroxidase was prepared using the general procedure of Example 1 of US-A-5,162,219, incorporated herein by reference.
- the hapten was conjugated to amine-enriched horseradish peroxidase by dissolving "HD-2" (15.5 mg) in dry N,N-dimethylformamide (1.031 ml) containing 4'-hydroxyacetanilide (10 mmolar).
- a solution of amine-enriched horseradish peroxidase (1 ml, 10 mg/ml) in N-(2-hydroxyethyl)piperazine-N'-(3-propanesulfonic acid) buffer (pH 8, 0.1 molar) was combined with N,N-dimethylformamide (500 ⁇ l) containing 4'-hydroxyacetanilide (10 mmolar) with vortex mixing and then was placed in a 42°C water bath.
- the "HD-2" solution 500 ⁇ l was added dropwise to the enzyme solution with vortex mixing so that the molar ratio was 50:1.
- the reaction mixture was incubated for 1 hour at 42°C with gentle agitation.
- the reaction product was dialyzed as follows:
- the product solution contained 1.48 mg/ml of diphenylhydantoin-horseradish peroxidase conjugate, as determined by spectrophotometry.
- Anti-digoxin monoclonal antibodies were attached to poly[styrene- co - p -(2-chloroethylsulfonylmethyl)styrene] (95:5 weight ratio, 1.0 ⁇ m average diameter) beads using the procedures described in US-A-5,177,023 (Sutton et al). Similarly, anti-diphenylhydantoin monoclonal antibodies were attached to polymeric particles for use in Example 3 below.
- TRITONTM X-100 nonionic surfactant is available from Union Carbide.
- TETRONICTM T908 nonionic surfactant is available from BASF, and Olin 10G nonionic surfactant is available from Olin Corporation. All other reagents and components used in the elements and methods are either available commercially or readily prepared using conventional starting materials using known procedures.
- Dry analytical elements of this invention useful for the detection of digoxin were prepared using conventional procedures and having the following coating formulations.
- the gravure and receptor coatings diffused into the porous spreading coating to form separate zones near the boundaries of the dried porous spreading layer.
- the element identified as Example 1 contained a modified apo-horseradish peroxidase having carboxymethylated histidine amino acids in the gravure coating.
- the element identified as Example 2 contained the same modified apo-horseradish peroxidase from a different manufacturing batch.
- a Control element was identical in every respect except that unmodified apo-horseradish peroxidase was used in place of the modified apo-horseradish peroxidase in the gravure coating.
- the rate of signal formation was determined by applying a test sample (11 ⁇ l) containing digoxin in a human serum-based matrix to the element, and incubating the element for 5 minutes at 37°C.
- the element was kept at 37°C while measurement of the rate of dye formation was carried out over about 2.5 minutes at 670 nm using conventional reflectance densitometry.
- test sample was spiked with both a hemolysate produced by sonicating whole blood to provide the amount of hemoglobin indicated in Table I below, and digoxin (2 ng/ml).
- the test samples having 8 mg/dl of hemoglobin were assayed using a conventional radioimmunoassay method [Bayse et al, "Reference Method for Digoxin by Radioimmunoassay, Proposed Standard (1985)", National Committee for Clinical Laboratory Standards (NCCLS) Document I/LA9-P, NCCLS: Villanova, PA, 1986] to provide a benchmark measurement of digoxin (1.87 ng/ml).
- Analytical elements were prepared similarly to those described above in Examples 1 and 2 except that they had reagents suitable for detection of diphenylhydantoin.
- the elements were coated using conventional procedures and equipment and had the following basic coating compositions and structure:
- test samples were used to assay two patient test samples for diphenylhydantoin obtained from Jackson Memorial Hospital (Miami, Florida), which samples were known to contain various amounts of analyte as well as blood protein interferents which are known to positively bias the test results in the absence of unmodified apo-horseradish peroxidase.
- the test samples are identified herein as "Patient 1" and "Patient 2".
- a third test sample identified as "Patient 3" was obtained from an employee of Eastman Kodak Company, which sample contained no known amount of analyte. To this third test sample, however, was added 20 ⁇ g/ml of analyte.
- the data in the first set of bar graphs of FIG. 1 were obtained using an analytical element containing 10 mg/m of unmodified apo-horseradish peroxidase in the gravure coating but prepared in a different manufacturing process than the other elements containing unmodified apo-horseradish peroxidase.
- the data in the last two sets of bar graphs (series B) of FIG. 1 were obtained using elements of the present invention containing modified apo-horseradish peroxidase having carboxymethylated histidine amino acids.
- the first bar graph in each set of bar graphs shows the results from "Patient 1" test sample
- the second bar graph shows the results from "Patient 2" test samples
- the third bar graph shows the results from "Patient 3" test samples.
- FIG. 1 show that assays carried out without apo-horseradish peroxidase of any type exhibited considerably more bias than the other assays. As the level of unmodified apo-horseradish peroxidase was increased, the amount of bias was decreased, but the ultimate improvement for most patient samples was obtained with the elements of the present invention containing modified apo-enzyme.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
- This invention relates to analytical elements, compositions and methods for using them to detect an analyte using peroxidase or a peroxidase-labeled specific binding reagent. In particular, it relates to the reduction of hemoglobin bias in the detection of such analytes as well as the reduction of bias from other known protein interferents.
- There is a continuing need in medical practice and research, and in analytical and diagnostic procedures for rapid and accurate determinations of chemical and biological substances which are present in various fluids, such as biological fluids. For example, the presence of proteins, hormones, drugs, viruses, microorganisms, narcotics and steroids must be determined accurately and rapidly for effective research, diagnosis and treatment.
- A wide variety of analytical methods have been developed in recent decades to detect the noted substances. The methods have become highly reliable and in some instances, suitable for automation, as well as suitable for use in kit form. Most of such methods rely on what are known in the art as "specific binding reactions" between a substance to be detected (identified herein as a "specific binding ligand" or "ligand") and a corresponding "receptor" which recognizes and reacts with the ligand specifically. Most well known specific binding reactions are between immunoreactants (in "immunoassays"), such as antibodies with haptens or antigens, but others also are known (such as avidin with biotin and a sugar with a lectin).
- In general, specific binding assays can provide a qualitative or quantitative determination (or both) of the presence or absence (or quantity) of an analyte of interest. In one form of assay known as a "competitive binding immunoassay", a labeled analog of the ligand to be determined is placed in competition with a fixed amount of an appropriate antibody which can react with both the ligand and the ligand analog. The label on the analog can be appropriately detected in its "free" or complexed (that is, reacted) form. Signal level then will tell the user how much ligand is in the sample being tested.
- In an alternative immunoassay format known as a "sandwich" immunoassay or immunometric assay, the ligand is contacted with two or more receptor molecules which bind to the ligand at different epitopic sites. One receptor is typically appropriately labeled and the other is either immobilized on a solid substrate, or is capable of being immobilized thereon. The amount of ligand is directly proportional to the amount of bound complex among the ligand and the two receptors.
- Immunoassays have been traditionally carried out in solution or in test devices where fluids are removed in some fashion from the reagents participating in the assay. Dry analytical elements and their use for immunoassays are described in numerous publications, including US-A-4,258,001 (Pierce et al), US-A-4,670,381 (Frickey et al), WO 82/2601 (published August 5, 1992), EP-A-0 051 183 (published May 12, 1982) and EP-A-0 066 648 (published December 15, 1982).
- Improved dry analytical elements and their use in immunoassays are described in EP-A-0 587 222 in which enzyme labels are utilized for detection. Peroxidase is the preferred enzyme label. Such elements allow for the detection of analytes present in very low concentrations.
- In the immunoassays carried out in the dry analytical elements using peroxidase as the label, results may be altered by the presence of materials in test samples that affect the activity of the enzyme. These interfering effects can be overcome by including in the assay system, materials that block the effect of the interferents.
- WO 86/07462 (published December 18, 1986) describes the use of certain modified forms of peroxidase to reduce the effect of interferents in solution assays. Those forms include apo-horseradish peroxidase, carboxymethylated apo-horseradish peroxidase and acidic forms of horseradish peroxidase.
- However, when apo-horseradish peroxidase was added in excess (100 fold excess of the horseradish peroxidase label) to coated elements for immunoassays to reduce the effect of interferents, a significant increase in hemoglobin bias was observed. It is believed that this effect was due to reactivation of apo-horseradish peroxidase by hemoglobin. Because the apo-horseradish peroxidase is necessarily present in high concentrations, activation of this material generates considerable signal and introduces large errors in the assays.
- Thus, there is a need for a way to reduce the interference in coated immunoassays using a peroxidase as the label without causing a bias of the results by hemoglobin in the test sample.
- The noted problems have been solved with an analytical element for the determination of an analyte comprising a porous spreading layer, and containing, independently, in the same or different layer as the porous spreading layer,
- a) a peroxidase or a peroxidase-labeled specific binding reagent, and
- b) an apo-peroxidase comprising modified histidine amino acids.
- The present invention also provides a method for the determination of an analyte comprising:
- A) contacting a fluid sample suspected of containing a specific binding ligand and hemoglobin with an analytical element comprising:
a porous spreading layer, and
one or more additional layers which are in fluid contact with the porous spreading layer,
the element containing in at least one of the layers:
a peroxidase-labeled immunoreactant which specifically binds to either the specific binding ligand or a receptor therefor, or
an unlabeled immunoreactant which specifically binds to either the specific binding ligand or a receptor therefor, and
the element further containing, independently, in at least one of the layers,
an apo-peroxidase comprising modified histidine amino acids,
to bring about a separation of the unreacted form of the peroxidase-labeled immunoreactant from the reacted form of the peroxidase-labeled immunoreactant, and - B) detecting either the unreacted or reacted form of the peroxidase-labeled immunoreactant as a measure of the specific binding ligand of interest.
- Further an analytical composition of this invention comprises:
- a) a peroxidase or a peroxidase-labeled specific binding reagent,
- b) an apo-peroxidase comprising modified histidine amino acids,
- c) one or more reagents which react to provide a colorimetric or chemiluminescent signal in the presence of a peroxidase, and
- d) a phenol or aniline coreagent for c).
- The present invention provides an accurate method for detecting an analyte using a peroxidase or a peroxidase-labeled specific binding reagent. The invention is particularly advantageous using a dry analytical element in the assay. The effects of known interferents to peroxidase labels are minimized as expected, and bias from the presence of hemoglobin is unexpectedly avoided.
- These advantages are achieved by using in the assay, a form of apo-peroxidase which has been modified to block the histidine amino acids of the protein so the enzyme cannot be reactivated by hemoglobin. Blocking can be accomplished by substitution on at least one of the nitrogen atoms of the histidine imidazolyl groups as described in more detail below.
- The modified apo-peroxidase remains effective to reduce the interfering effects by other common serum protein interferents. The art teaches that unmodified apo-peroxidase should be equally useful as modified forms of the enzyme, such as carboxymethylated apo-peroxidase, to remove interferents in solution assays. Yet, in the dry assay format, the unmodified apo-peroxidase causes additional bias in the assay resulting from the presence of hemoglobin. The present invention addresses this problem and provides a further improvement.
- FIG. 1 is a graphical representation of assay data (bias vs. coating levels) obtained using various analytical elements from three patient samples, as described in detail in Example 3 below.
- The present invention can be practiced to advantage in any analytical method designed to generate a colorimetric, fluorometric or chemiluminescent signal in response to the presence of peroxidase. Such assays can involve the detection of an organic or inorganic peroxide (such as hydrogen peroxide) or peroxidase (in its free form), or the detection of a non-immunological analyte other than peroxidase using reaction schemes which involve the reaction of peroxidase. In preferred embodiments, the invention is directed to the practice of specific binding assays.
- The assay can be qualitative, quantitative or semi-quantitative to detect one or more of a wide variety of analytes in aqueous liquids, such as human and animal biological fluids, waste fluids, foods, environmental effluent, chemical processing liquids and other specimens readily apparent to one skilled in the art. Biological fluids, such as human or animal serum, plasma or urine are preferably assayed with this invention.
- Hydrogen peroxide (or another peroxide) can be determined with this invention as well as analytes capable of producing peroxide. That is, the analyte may be capable of participating in one or more reactions which produce hydrogen peroxide which then is detected using suitable signal-producing reagents and a peroxidase.
- The present invention is particularly advantageous in assays where the peroxidase is used in a rate limiting fashion. In most instances, such assays are specific binding assays wherein the peroxidase is used as a label on one of the immunoreactants needed to detect a specific binding ligand. However, a skilled clinical chemist would readily understand that there may be assays for metabolites, enzymes or other non-immunoreactive analytes wherein peroxidase also is used in a rate limiting fashion. Therefore, the present invention is not intended to be limited to specific binding assays.
- Analytical compositions of this invention which are useful in solution assays can include a peroxidase or a peroxidase-labeled specific binding reagent, a modified apo-peroxidase (defined below), one or more reagents for producing a signal (defined below), and optionally, a phenol or aniline "coreagent" for those signal-producing reagents.
- Coreagents which can be used in this manner include compounds which are variously known as "electron transfer agents" for producing dye signals, such as the phenols and anilines described for example, in US-A-4,828,983 (McClune), and as "enhancers" for producing chemiluminescent signals as described, for example in US-A-4,729,950 (Kricka et al) and US-A-4,598,044 (Kricka et al). All three of these patents are incorporated herein by reference. Other useful coreagents are described in EP-A-0 603 954.
- Three preferred coreagents are 4'-hydroxyacetanilide, 3'-chloro-4'-hydroxyacetanilide and 3',5'-dichloro-4'-hydroxyacetanilide.
- In the described analytical compositions, the peroxidase or peroxidase-labeled specific binding reagent, and signal-generating reagents can be present in any suitable concentration which would be readily apparent to the skilled artisan. The modified apo-peroxidase is generally present in an amount of from about 10⁻⁹ to about 10⁻³, with from about 10⁻⁷ to about 10⁻⁵ being preferred. The phenol or aniline coreagent can be present in an amount of from about 0.001 to about 150 mmolar, with from about 0.01 to about 50 mmolar being preferred. It would be readily apparent to a skilled worker as to how adjustments of the various amounts should be made in a given composition for a given analyte.
- In a preferred embodiment, the present invention is directed to an element and method for detecting target specific binding ligands (identified as ligands hereinafter) for which receptor molecules are available or manufacturable. Examples of ligand-receptor complexes (that is, a reaction product of ligand and corresponding receptor) include, but are not limited to, antibody-antigen, antibody-hapten, avidin-biotin, sugar-lectin, gelatin-fibronectin and Protein A-IgG complexes. For the purposes of this invention, complementary nucleic acids (that is, hybridized products of complementary strands) also are considered ligand-receptor complexes.
- Ligands include, but are not limited to, peptides, polypeptides, proteins (including enzymes, antibodies, antigenic proteins, glycoproteins, lipoproteins and avidin), hormones (such as thyroxine, triiodothyronine, human chorionic gonadotropin, estrogen, ACTH and substance P), vitamins, human immune system modulators (such as interleukin-6), steroids, carbohydrates (such as polysaccharides), glycolipids, drugs (such as digoxin, phenytoin, phenobarbital, morphine, carbamazepine and theophylline), antibiotics (such as gentimicin), components of cells and viruses (such as Streptococcal species, herpes viruses, Gonococcal species, Chlamydial species, retroviruses, influenza viruses, Prevotella species, Porphyromonas species, Actinobacillus species and Mycobacterium species), nucleic acids (including single- and double-stranded oligonucleotides), pharmaceuticals, haptens, lectins, biotin, and other materials readily apparent to one skilled in the art.
- However, this invention is particularly advantageous for using dry analytical elements to detect analytes wherein the peroxidase-labeled specific binding reagent is present in the element in rate limiting amounts.
- In the preferred specific binding assays, analytes which can be so determined in solution or dry formats using peroxidase as a rate limiting reactant include, but are not limited to, diphenylhydantoin (or phenytoin), carbamazepine, phenobarbital, C-reactive protein, digoxin, a thyronine derivative (such as thyroxine and triiodothrionine), morphine, theophylline, gentamicin, vancomicin, tobramicin, TSH, hCG, various proteins (such as IgM, IgG, IgE and IgA proteins), creatine kinase-MB, troponins T and I, and apoproteins A, A1 and B. The various other reagents which would be needed for detecting the analyte in such assays are well within the skill of the ordinary clinical chemist. Thus, for example, one or more conventional reagents would be used along with peroxidase to produce a colorimetric, fluorescent or chemiluminescent signal after one or more reactions.
- As used herein, the term "antibody" includes whole immunoglobulin molecules having a single specificity as is conventional in the art. In addition, the term is intended to include chemically prepared fragments [such as Fab, F(ab) ', F(ab)₂ fragments] of such molecules and genetically prepared equivalents thereof (such as "single chain antibody fragments" or ScFv fragments). The antibodies can be monoclonal or polyclonal.
- The present invention is preferably carried out using an analytical element comprising a porous spreading layer (usually a coated layer) which has a suitable porosity for accommodating a test sample, diluted or undiluted. Preferably, the porous spreading layer is isotropically porous, meaning that it is equally porous in every dimension so that fluids spread uniformly in every dimension, as provided by interconnected fibers, particles and other components of the layer. Materials useful for preparing such elements are well known. The porous layers can be composed of cellulosic, glass or polymeric fibers, polymeric or inorganic particulate materials or a combination of such materials. Details about conventional spreading layers are provided, for example, in US-A-3,992,158 (Przybylowicz et al), US-A-4,258,001 (Pierce et al), US-A-4,292,272 (Kitajima et al) and US-A-4,430,436 (Koyama et al), all incorporated herein by reference. The preferred porous spreading layers are beaded spreading layers prepared from polymeric particles and a polymer adhesive as described in the Pierce et al patent.
- The element can include additional layers besides the porous spreading layers as long as all the layers are in fluid contact, meaning that fluids can move readily from one layer to another, even if such reagents do not readily move from one layer to another. Such additional layers are usually coated layers of various binder materials and one or more reagents useful in the assay, and include what are known in the art as subbing, reagent, registration and radiation blocking layers. Materials useful as binders in such layers are well known as described in the patents noted in the preceding paragraph, and preferably include gelatin (hardened or unhardened), hydrophilic acrylamide and vinylpyrrolidone polymers. Some layers may be water-insoluble while others are water-soluble or water-swellable so they dissolve or swell during an assay. It also is likely that some layers blend together during coating so that horizontal zones are formed in a single dried layer from different coating formulations.
- The layers of the element can be self-supporting, but preferably they are disposed on a suitable dimensionally stable, nonporous, chemically inert support. Useful support materials include polymeric films, metal foils, paper and other materials well known in the art. A transparent polyester support is preferred.
- The peroxidase or peroxidase-labeled specific binding reagent used in the practice of the present invention is included in one or more layers of the element. This reagent is capable of binding to either the specific binding ligand of interest or its corresponding receptor. In competitive binding immunoassays, the labeled reagent is usually a labeled analog of the specific binding ligand (such as labeled haptenic derivatives of the ligand). In sandwich assays, the labeled immunoreactant can be a labeled receptor for the ligand, or it can be a labeled molecule (such as a labeled anti-antibody) which binds to the receptor (such as an antibody).
- Labeled specific binding reagents can be prepared using any of a number of known procedures, and many of such reagents are commercially available from a number of sources. Preparatory procedures include those described by Yoshitake et al Eur.J.Biochem. 101, 395, 1979 and in US-A-5,106,732 (Kondo et al).
- By "peroxidase" in this application is meant any peroxidative substance (enzymatic or otherwise) which catalyzes the oxidation of a substrate, such as a leuco dye, in the presence of hydrogen peroxide or other oxidant to produce an appropriate signal. Microbial, fungal or plant peroxidases are preferred with horseradish peroxidase being most preferred.
- The amount of a peroxidase-labeled specific binding reagent in an element of this invention can vary widely due to the amount of the other components used in the reaction and the suspected amount of analyte in the test sample. Generally, the amount present in the element is at least about 2 µg/m, with from about 4 to about 25 µg/m being preferred.
- The peroxidase-labeled specific binding reagent useful in this invention is preferably a peroxidase-labeled hapten derivative of the ligand or a peroxidase-labeled antibody. However, a conjugate of avidin or another specific binding compound with peroxidase also can be used in the practice of this invention. Where the label is on a hapten, for example, it can be a peroxidase-labeled drug, hormone, protein, metabolite, chelate or haptenic derivative of any of these. Examples of such materials include, but are not limited to, peroxidase-labeled haptenic derivatives of digoxin, diphenylhydantoin, phenobarbital, C-reactive protein, a thyronine derivative such as thyroxine, carbamazepine or another analyte described above.
- A critical reagent used in the practice of this invention is a modified apo-peroxidase. These proteins have been modified by blocking the imidazolyl groups in the histidine amino acid molecules in the protein amino acid chain. The imidazolyl groups are blocked in at least one of the nitrogen atoms of the ring by substitution with any alkylating, condensation or addition reagent which sufficiently disrupts the stereo configuration of the histidine amino acids to prevent restoration of the peroxidase activity in the apo-peroxidase molecule, but does not alter the specific immunicity of the protein. The nitrogen atoms are blocked by the covalent attachment of an alkyl, aryl, alkanoyl, aroyl, alkoxycarbonyl, aryloxycarbonyl, alkylaminocarbonyl, or arylaminocarbonyl group thereto with an appropriate modifying addition, condensation or alkylating reagent.
- Examples of such useful modifying addition reagents include active halogen alkylating agents of any type such as:
- (1) halomethylcarbonyl group-containing compounds such as chloroacetic acid and its amides and esters, iodoacetic acid and its amides and esters, and bromoacetic acid and its amides and esters,
- (2) haloethylcarbonyl and haloethylsulfonyl group-containing compounds such as 3-chloropropionic acid and its esters, 3-chloropropiophenone and 3-chloropropionamide,
- (3) arylmethyl halides such as benzyl chloride, 1-chloromethyl-2-methylnaphthalene, 1-chloromethylnaphthalene, 4-chloromethylbiphenyl and 4-chloromethylbenzoic acid, and
- (4) acid halides such as acetyl chloride, propionyl chloride, benzoyl chloride and naphthoyl chloride.
- Other useful modifying reagents include anhydrides (such as acetic anhydride, phthalic anhydride, diethyl pyrocarbonate and succinic anhydride), active esters (such as N-acetoxysuccinimide, N-proprionyloxysuccinimide and others as described in GB 2,064,800A), vinylsulfonyl and vinylcarbonyl group-containing compounds (such as vinylsulfonamide, sodium vinylsulfonate, sodium acrylate, sodium methacrylate, ethyl acrylate and others readily apparent to one skilled in the art), isocyanates (such as butyl isocyanate, p-bromophenyl isocyanate and phenyl isocyanate), aldehydes (such as benzaldehyde, acetaldehyde and propionaldehyde), and epoxides (such as glycidol).
- One technique for carrying out this modification is to react the apo-peroxidase with diethyl pyrocarbonate using a procedure described essentially by Miles in Methods in Enzymology 47, pages 431-442 (1977). Specific details for this procedure are provided in Preparation 1 below. The result is a modified apo-peroxidase having histidine amine acids substituted with ethoxycarbonyl groups.
- An alternative and preferred technique comprises carboxyalkylating the apo-peroxidase using a suitable reagent such as iodoacetic acid, chloroacetic acid or bromoacetic acid. Details regarding such a technique are provided by Gurd in Methods in Enzymology, 11, pages 532-541 (1967). For example, the apo-peroxidase can be a carboxyalkylated derivative (that is, having carboxyalkylated histidine amino acids), as described below in Preparation 2 prior to the examples.
- The modified apo-peroxidase is present in the element of this invention in an amount of from about 0.1 to about 100 mg/m, and preferably at a coverage of from about 0.5 to about 20 mg/m. A preferred coverage is shown in the examples below.
- Peroxidase or a peroxidase-labeled specific binding reagent, and the modified apo-peroxidase are, independently, in the same or different layers of the element of this invention. Moreover, they can be independently in the porous spreading layer or in any additional layer of the element or in independent zones of a single layer (such as the porous spreading layer).
- In one embodiment of this invention, a multilayer analytical element for the determination of a specific binding ligand of interest comprises a nonporous support having thereon, in fluid contact:
a first reagent or buffer layer,
a receptor layer comprising an unlabeled immunoreactant which specifically binds to either the specific binding ligand of interest or a receptor therefor,
a porous spreading layer containing a reagent which provides a colorimetric or chemiluminescent signal in the presence of hydrogen peroxide and a peroxidase, and
contiguous to the porous spreading layer, a second reagent layer containing:
a peroxidase-labeled immunoreactant which specifically binds to either the specific binding ligand of interest or a receptor therefor, and
a modified apo-horseradish peroxidase as defined above. - In a preferred embodiment of this invention, a multilayer analytical element for the determination of a specific binding ligand of interest comprises a nonporous support having thereon, in fluid contact:
a first reagent or buffer layer, and
a porous spreading layer containing a reagent which provides a colorimetric or chemiluminescent signal in the presence of hydrogen peroxide and a peroxidase,
the porous spreading layer having multiple zones, including
a first zone containing an unlabeled immunoreactant which specifically binds to either the specific binding ligand of interest or a receptor therefor, and
a second zone containing a peroxidase-labeled immunoreactant which specifically binds to either the specific binding ligand of interest or a receptor therefor, and a modified apo-horseradish peroxidase as defined above. - In this element, the zones of the porous spreading layer can be horizontal or vertical regions of the layer. More preferably, they are horizontal zones created by separate coatings applied before or after coating application of the porous spreading layer components. During the coating process to prepare the element, the separate coatings (for example, the formulations used for separate second reagent and receptor layers) may dissolve into the porous spreading layer forming a single dried layer with multiple zones. One technique for doing this by gravure coating technology is described in more detail in EP-A-0 517 338.
- In still another embodiment, the element is similar to the preferred element but the unlabeled immunoreactant, peroxidase-labeled immunoreactant and modified apo-horseradish peroxidase are distributed throughout the porous spreading layer.
- The element of this invention also can contain an unlabeled immunoreactant which is capable of specifically reacting with either the specific binding ligand of interest or its receptor. In competitive binding immunoassays, this immunoreactant is generally a receptor (such as an antibody) to the ligand. In sandwich immunoassays, the unlabeled immunoreactant can be receptor for the ligand, or a binding molecule reactive with the receptor (such as an anti-antibody). In preferred embodiments, the immunoreactant is an antibody specific to the ligand.
- The unlabeled immunoreactant and peroxidase-labeled immunoreactant are generally kept separated in some fashion in the element until the assay has begun. They may be separated by locating them in different layers of the element, or they may be in the same layer, but one component is encapsulated with a material that releases the component when the assay is begun, or they are can be located in separate zones of the same layer.
- It also is preferred that the unlabeled immunoreactants be immobilized on suitable particles that are dispersed throughout a layer of the element. Such particles can be composed of any suitable material including, but not limited to, glass, iron oxides, ceramics, organic synthetic or naturally occurring polymers, and have an average particle size of from about 0.01 to about 10 µm. Preferably, the particles are prepared from synthetic polymers and have suitable surface groups for adsorption or covalent attachment of the immunoreactant molecules. A wide variety of such materials are known in the art, such as those described in US-A-4,828,978 (Warren III et al), US-A-4,997,772 (Sutton et al), US-A-5,147,777 (Sutton et al), US-A-5,177,023 (Sutton et al), all incorporated herein by reference.
- Particularly useful polymeric particles are those prepared from ethylenically unsaturated polymerizable monomers having reactive carboxy, 2-substituted ethylsulfonyl or vinylsulfonyl groups as described in the patents noted in the preceding paragraph.
- With the use of peroxidase as the label in the method of this invention, there is a need to bring the peroxidase-labeled immunoreactant into contact with hydrogen peroxide or a similar oxidant and the appropriate reagents to produce a colorimetric or chemiluminescent signal. Useful reagents for providing a colorimetric signal include, but are not limited to, imidazole or triarylmethane leuco dyes, such as those described in US-A-4,089,747 (Bruschi) and references noted therein, US-A-4,670,385 (Babb et al), EP-A-0 122 641 (published October 24, 1984) and Japanese Patent Publication 58(1983)-045557. Other useful reagents would be readily apparent to a skilled worker in view of the considerable amount of literature in this field. The triarylimidazole leuco dyes of the Bruschi patent noted above, incorporated herein by reference, are preferred in the practice of this invention. Such leuco dyes are either commercially available or readily prepared using known procedures and starting materials.
- Diazonium and tetrazolium salts also are useful as long as they can provide a chromophore in the presence of peroxidase and an oxidant. A diazonium salt is generally an organic salt of a compound having a diazonium radical. Tetrazolium salts are organic salts in which the organic portion contains one or two tetrazole rings, generally having aryl substituents, at various positions.
- Many useful diazonium and tetrazolium compounds are described for example, in US-A-3,905,872 (Forgione), US-A-4,772,553 (Fujii et al), US-A-4,892,817 (Pawlak) and US-A-4,892,833 (Weiss et al), some of which are available from commercial sources or readily prepared using known procedures and starting materials.
- Chemiluminescent signals can be generated using a variety of known reagents. A preferred chemiluminescent signal generating reagent is a 2,3-dihydro-1,4-phthalazinedione derivative (identified herein as "DPD"). Any free or conjugated DPD that can be converted to an excited state in a chemiluminescent reaction and when returned to a non-excited state, emits light, is useful in the practice of this invention. A considerable number of such compounds are known in the art, including those described in US-A-4,598,044 (Kricka et al) and Chemiluminescence in Organic Chemistry, Gundermann and McCapra, Springer-Verlag, Berlin, 1987, pages 204-207. Such compounds are generally known as "luminol type hydrazides" and include phthalic hydrazides, naphthalene-1,2-dicarboxylic acid hydrazides, anthracene-2,3-dicarboxylic acid hydrazides, phenathrene-1,2-dicarboxylic acid hydrazides, fluorene-1,2-dicarboxylic acid hydrazides, benzo[g,h,i]perylene-1,2-dicarboxylic acid hydrazides, coronene-1,2-dicarboxylic acid hydrazides, and others readily apparent to one skilled in the art. Luminol is a preferred chemiluminescent signal generating reagent. Various phenols and anilines are used as enhancers with DPD compounds.
- The elements of this invention also can include a variety of addenda which are common to such elements to aid in manufacture, fluid spreading, absorbance of unwanted radiation and receptor stability.
- The element can be prepared using conventional coating procedures and equipment which are described in considerable art (including gravure, curtain, hopper and other coating techniques). The elements can be configured in a variety of forms and shapes, including elongated tapes of any desired width, sheets, slides or chips.
- Further, the method of this invention can be manual or automated using appropriate analytical equipment and procedures. Generally, the method includes contacting the reagents in the element by spotting a test sample (for example, 1 to 200 µl) on the porous spreading layer. The movement of fluid within the element effectively mixes the reagents for the reactions to take place. After sample application, the element is exposed to any condition, such as incubation, heating or another procedure, that may be desirable to quicken or otherwise facilitate the reactions in the element (as well as any specific binding complexes in immunoassays).
- For immunoassays, in some instances, a suitable signal for a quantitative result can be obtained without effective separation of the reacted (bound) and unreacted (unbound) forms of the peroxidase-labeled immunoreactant. However, it is preferred that the forms be separated within a zone of the element, as is typical in what are known as heterogeneous immunoassays. Thus, a signal can be evaluated in a defined region of the zone.
- Applying a substrate solution (for example 5 to 200 µl) to the zone of the element is the preferred method for affecting this separation and obtaining the appropriate signal. Any desired rate and manner of application of the substrate solution can be used. This solution may contain a substrate for the peroxidase or other signal producing reagents, or merely be a buffered wash solution. When the preferred leuco dyes (described above) or luminol type compounds are used in the element, the substrate solution preferably contains a phenolic signal enhancer or electron transfer agent, many of which are known in the art. A preferred compound is 4'-hydroxyacetanilide. The amounts of the reagents in the substrate solution would be readily apparent to one skilled in the art.
- The following examples are illustrative of the invention and not meant to be limiting. All percentages are by weight, unless otherwise indicated.
- A modified apo-horseradish peroxidase was prepared by dissolving apo-horseradish peroxidase (1.1 g) in water (7 ml), diethyl pyrocarbonate (0.94 g) was added with stirring, and the resulting mixture was incubated with mixing at 24°C for 2 hours. Incubation was continued, with stirring, at 4°C for 18 additional hours. The resulting product mixture (21.5 ml) was dialyzed against two changes of phosphate buffer (3 liters, 10 mmolar, pH 7). The dialyzed mixture contained an apo-horseradish peroxidase (40 mg/ml) having ethoxycarbonyl groups on the imidazolyl groups of the histidine amino acids.
- An alternative modified apo-horseradish peroxidase was prepared by adding apo-horseradish peroxidase (3%) to a buffered solution of iodoacetic acid (3%, pH 5.5), and mixed at 24°C for 24 hours. The resulting product solution was dialyzed against 2 changes of water (3 liters) at 24°C for 24 hours. Analysis of the dialyzed mixture confirmed the presence of apo-horseradish peroxidase having imidazolyl groups substituted with carboxymethyl groups at a yield of about 85%.
- The peroxidase-labeled digoxin analog used in the elements was prepared by the procedures and from reagents described in EP-A-0 468 590 and EP-A-0 468 591.
- A water-soluble conjugate of a diphenylhydantoin hapten and amine-enriched horseradish peroxidase was prepared as follows. This preparation is representative only. Alternative preparative methods also exist.
- The hapten, 5,5-diphenyl-3-{4-[4-(3-succinimidoxycarbonylpropionyl)-1-piperazinylcarbonyl]butyl}-2,4-imidazolidinedione, was prepared by procedures described in EP-A-0 517 327 (published May 5, 1993). It is identified as "HD-2" in that publication. Amine-enriched horseradish peroxidase was prepared using the general procedure of Example 1 of US-A-5,162,219, incorporated herein by reference.
- The hapten was conjugated to amine-enriched horseradish peroxidase by dissolving "HD-2" (15.5 mg) in dry N,N-dimethylformamide (1.031 ml) containing 4'-hydroxyacetanilide (10 mmolar). A solution of amine-enriched horseradish peroxidase (1 ml, 10 mg/ml) in N-(2-hydroxyethyl)piperazine-N'-(3-propanesulfonic acid) buffer (pH 8, 0.1 molar) was combined with N,N-dimethylformamide (500 µl) containing 4'-hydroxyacetanilide (10 mmolar) with vortex mixing and then was placed in a 42°C water bath. The "HD-2" solution (500 µl) was added dropwise to the enzyme solution with vortex mixing so that the molar ratio was 50:1. The reaction mixture was incubated for 1 hour at 42°C with gentle agitation.
- The reaction product was dialyzed as follows:
- a) Against a mixture of N,N-dimethylformamide (1 liter) containing 4'-hydroxyacetanilide (10 mmolar) and the buffer noted above (pH 8, 0.1 molar) at a 1:1 ratio at 42°C for 1 hour.
- b) Dialysis condition a) was repeated.
- c) Against the noted buffer (1.5 liters, 0.1 molar, pH 8) containing bovine serum albumin (0.1%) at 8°C for 1.5 hours.
- d) Against the noted buffer (1.5 liters, 0.1 molar, pH 8) at 8°C for 18 hours.
- e) Against tris(hydroxymethyl)aminomethane hydrochloride buffer (1.5 liters, 0.04 molar, pH 7.5) containing sodium chloride (0.15 molar) at 8°C for 2 hours.
- f) Dialysis condition e) was repeated for 4 hours.
- The product solution contained 1.48 mg/ml of diphenylhydantoin-horseradish peroxidase conjugate, as determined by spectrophotometry.
- Anti-digoxin monoclonal antibodies were attached to poly[styrene-co-p-(2-chloroethylsulfonylmethyl)styrene] (95:5 weight ratio, 1.0 µm average diameter) beads using the procedures described in US-A-5,177,023 (Sutton et al). Similarly, anti-diphenylhydantoin monoclonal antibodies were attached to polymeric particles for use in Example 3 below.
- TRITON™ X-100 nonionic surfactant is available from Union Carbide. TETRONIC™ T908 nonionic surfactant is available from BASF, and Olin 10G nonionic surfactant is available from Olin Corporation. All other reagents and components used in the elements and methods are either available commercially or readily prepared using conventional starting materials using known procedures.
- Dry analytical elements of this invention useful for the detection of digoxin were prepared using conventional procedures and having the following coating formulations. The gravure and receptor coatings diffused into the porous spreading coating to form separate zones near the boundaries of the dried porous spreading layer.
- The element identified as Example 1 contained a modified apo-horseradish peroxidase having carboxymethylated histidine amino acids in the gravure coating. The element identified as Example 2 contained the same modified apo-horseradish peroxidase from a different manufacturing batch.
- A Control element was identical in every respect except that unmodified apo-horseradish peroxidase was used in place of the modified apo-horseradish peroxidase in the gravure coating.
- The rate of signal formation was determined by applying a test sample (11 µl) containing digoxin in a human serum-based matrix to the element, and incubating the element for 5 minutes at 37°C. A substrate solution (12 µl) containing hydrogen peroxide (0.04%), 4'-hydroxyacetanilide (5 mmolar) and diethylenetriaminepentaacetic acid (10 µmolar) in a sodium phosphate buffered surfactant solution (0.01 molar buffer, pH 6.8) then was applied.
- Immediately following application of the substrate solution, the element was kept at 37°C while measurement of the rate of dye formation was carried out over about 2.5 minutes at 670 nm using conventional reflectance densitometry.
- Each test sample was spiked with both a hemolysate produced by sonicating whole blood to provide the amount of hemoglobin indicated in Table I below, and digoxin (2 ng/ml). The test samples having 8 mg/dl of hemoglobin were assayed using a conventional radioimmunoassay method [Bayse et al, "Reference Method for Digoxin by Radioimmunoassay, Proposed Standard (1985)", National Committee for Clinical Laboratory Standards (NCCLS) Document I/LA9-P, NCCLS: Villanova, PA, 1986] to provide a benchmark measurement of digoxin (1.87 ng/ml).
- The results shown in Table I below show that considerable bias in the digoxin determination occurs using the Control element because the unmodified apo-horseradish peroxidase was reactivated (that is, had restored enzyme activity), producing unwanted signal in the presence of hemoglobin. Since the signal generated in the assays are inversely proportional to the amount of analyte in the test samples, the biased results are negative. The bias was reduced considerably using the elements of the present invention. That is, the results were only slightly negative or slightly positive.
Table I Element Hemoglobin Concentration (mg/dl) Digoxin Concentration (ng/ml) Bias Control 8 1.71 -0.17 47 1.56 -0.31 126 0.40 -1.47 195 0.02 -1.85 Example 1 8 1.87 0 47 1.79 -0.08 126 1.69 -0.19 195 1.57 -0.30 Example 2 8 1.90 0.03 47 1.91 0.04 126 1.77 -0.10 195 1.60 -0.27 -
- The elements were used to assay two patient test samples for diphenylhydantoin obtained from Jackson Memorial Hospital (Miami, Florida), which samples were known to contain various amounts of analyte as well as blood protein interferents which are known to positively bias the test results in the absence of unmodified apo-horseradish peroxidase. The test samples are identified herein as "Patient 1" and "Patient 2". A third test sample identified as "Patient 3" was obtained from an employee of Eastman Kodak Company, which sample contained no known amount of analyte. To this third test sample, however, was added 20 µg/ml of analyte.
- Reference assays were carried out on the test samples using HPLC, and then the elements described above were used. The results were determined using an EKTACHEM™ E-250 analyzer (Eastman Kodak Company), and any bias was determined by comparing the analyzer result with the result obtained by HPLC. The results of the assays are summarized in FIGURE 1 with the bias shown on the y-axis and various coating levels (mg/m) of modified or unmodified apo-horseradish peroxidase shown for the separate tests on the x-axis.
- The data in the first set of bar graphs of FIG. 1 were obtained using an analytical element containing 10 mg/m of unmodified apo-horseradish peroxidase in the gravure coating but prepared in a different manufacturing process than the other elements containing unmodified apo-horseradish peroxidase. The data in the last two sets of bar graphs (series B) of FIG. 1 were obtained using elements of the present invention containing modified apo-horseradish peroxidase having carboxymethylated histidine amino acids.
- The first bar graph in each set of bar graphs shows the results from "Patient 1" test sample, the second bar graph shows the results from "Patient 2" test samples, and the third bar graph shows the results from "Patient 3" test samples.
- The data in FIG. 1 show that assays carried out without apo-horseradish peroxidase of any type exhibited considerably more bias than the other assays. As the level of unmodified apo-horseradish peroxidase was increased, the amount of bias was decreased, but the ultimate improvement for most patient samples was obtained with the elements of the present invention containing modified apo-enzyme.
- The invention has been described in detail with particular reference to preferred embodiments thereof, but it will be understood that variations and modifications can be effected within the spirit and scope of the invention.
Claims (20)
- An analytical element for the determination of an analyte comprising a porous spreading layer, and containing, independently, in the same or different layer as said porous spreading layer,a) a peroxidase or a peroxidase-labeled specific binding reagent, andb) an apo-peroxidase comprising modified histidine amino acids.
- The element of claim 1 wherein said modified apo-peroxidase has carboxyalkylated histidine amino acids.
- The element of claim 1 wherein said modified apo-peroxidase has histidine amino acids substituted with ethoxycarbonyl groups.
- The element of claim 1 further comprising one or more additional layers which are in fluid contact with said porous spreading layer, and said a) and b), independently, being located in one or more zones of said porous spreading layer.
- The element of claim 1 wherein said peroxidase-labeled specific binding reagent is a peroxidase-labeled antibody.
- The element of claim 1 wherein said peroxidase-labeled specific binding reagent is a peroxidase-labeled drug, hormone, protein, metabolite, chelate or haptenic derivative of a drug, hormone, protein, metabolite or chelate.
- The element of claim 6 wherein said peroxidase-labeled specific binding reagent is a peroxidase-labeled haptenic derivative of digoxin, diphenylhydantoin, phenobarbital, C-reactive protein, a thyronine derivative, carbamazepine, gentomicin, vancomicin, tobramicin, thyroid stimulating hormone or human chorionic gonadotropin.
- A multilayer analytical element for the determination of a specific binding ligand of interest, said element comprising a nonporous support having thereon, in fluid contact:
a first reagent or buffer layer, and
a porous spreading layer containing a reagent which provides a colorimetric or chemiluminescent signal in the presence of hydrogen peroxide and a peroxidase,
said porous spreading layer having multiple zones including
a first zone containing an unlabeled immunoreactant which specifically binds to either the specific binding ligand of interest or a receptor therefor, and
a second zone containing a peroxidase-labeled immunoreactant which specifically binds to either the specific binding ligand of interest or a receptor therefor, and an apo-horseradish peroxidase comprising modified histidine amino acids. - The element of claim 8 wherein said modified apo-horseradish peroxidase has carboxyalkylated histidine amino acids or histidine amino acids substituted with ethoxycarbonyl groups, and which is present in a dry coverage of from about 0.1 to about 100 mg/m.
- The element of claim 8 wherein said unlabeled immunoreactant is an antibody specific to digoxin, diphenylhydantoin, phenobarbital, C-reactive protein, a thyronine derivative, carbamazepine, gentomicin, vancomicin, tobramicin, thyroid stimulating hormone or human chorionic gonadotropin.
- The element of claim 8 wherein said porous spreading layer is a beaded spreading layer.
- A method for the determination of an analyte comprising:A) contacting a fluid sample suspected of containing a specific binding ligand and hemoglobin with an analytical element comprising:
a porous spreading layer, and
one or more additional layers which are in fluid contact with said porous spreading layer,
said element containing in at least one of said layers:
a peroxidase-labeled immunoreactant which specifically binds to either said specific binding ligand or a receptor therefor, or
an unlabeled immunoreactant which specifically binds to either said specific binding ligand or a receptor therefor, and
said element further containing, independently, in at least one of said layers,
an apo-peroxidase comprising modified histidine amino acids,
to bring about a separation of the unreacted form of said peroxidase-labeled immunoreactant from the reacted form of said peroxidase-labeled immunoreactant, andB) detecting either said unreacted or reacted form of said peroxidase-labeled immunoreactant as a measure of said specific binding ligand of interest. - The method of claim 12 wherein said unreacted and reacted forms of said peroxidase-labeled immunoreactant are separated by applying a substrate solution to a zone of said element, said substrate solution containing a substrate for peroxidase.
- The method of claim 13 wherein said substrate solution further contains 4'-hydroxyacetanilide.
- The method of claim 13 wherein said reacted form of said peroxidase-labeled immunoreactant is reacted in the presence of an imidazole leuco dye to produce a colorimetric signal.
- The method of claim 13 wherein said fluid sample is a human or animal serum, plasma or urine sample.
- The method of claim 13 which is a competitive binding immunoassay wherein said element contains a peroxidase-labeled immunoreactant which is a peroxidase-labeled haptenic derivative of said specific binding ligand of interest.
- The method of claim 13 which is a sandwich assay wherein said element contains an unlabeled immunoreactant which is specifically reactive with said specific binding ligand of interest, said unlabeled immunoreactant being immobilized within said element.
- An analytical composition comprising:a) a peroxidase or a peroxidase-labeled specific binding reagent,b) an apo-peroxidase comprising modified histidine amino acids,c) one or more reagents which react to provide a colorimetric or chemiluminescent signal in the presence of a peroxidase, andd) a phenol or aniline coreagent for c).
- The composition of claim 19 wherein said modified apo-peroxidase has carboxyalkylated histidine amino acids, or histidine amino acids substituted with ethoxycarbonyl groups.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27739194A | 1994-07-19 | 1994-07-19 | |
US277391 | 1994-07-19 |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0693552A2 true EP0693552A2 (en) | 1996-01-24 |
EP0693552A3 EP0693552A3 (en) | 1996-04-03 |
EP0693552B1 EP0693552B1 (en) | 2003-04-02 |
Family
ID=23060663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP95305007A Expired - Lifetime EP0693552B1 (en) | 1994-07-19 | 1995-07-18 | Analytical element, composition and method using modified apo-horseradish peroxidase |
Country Status (7)
Country | Link |
---|---|
US (1) | US5776714A (en) |
EP (1) | EP0693552B1 (en) |
JP (1) | JP3715348B2 (en) |
AT (1) | ATE236246T1 (en) |
AU (1) | AU697785B2 (en) |
CA (1) | CA2154013C (en) |
DE (1) | DE69530148T2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998002570A1 (en) * | 1996-07-15 | 1998-01-22 | Roche Diagnostics Gmbh | Blood substitute suppression by peroxides |
EP0977034A2 (en) * | 1998-07-27 | 2000-02-02 | Bayer Corporation | Transparent flow through membrane for dry reagent analytical devices |
EP1307741A1 (en) * | 2000-07-26 | 2003-05-07 | Biodiagnostics, Inc. | Method for diagnosing thyroid conditions and for monitoring thyroxine therapy |
CN111518780A (en) * | 2020-06-04 | 2020-08-11 | 郑州伊美诺生物技术有限公司 | Preparation method of apo-horseradish peroxidase |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7183119B2 (en) * | 2004-11-15 | 2007-02-27 | Eastman Kodak Company | Method for sensitive detection of multiple biological analytes |
US7348147B2 (en) * | 2004-11-15 | 2008-03-25 | Carestream Health, Inc. | Method and system for nucleic acid detection |
US7074622B2 (en) * | 2004-11-15 | 2006-07-11 | Eastman Kodak Company | Method and system for sorting and separating particles |
JP5020324B2 (en) * | 2006-08-17 | 2012-09-05 | アトノミックス アクティーゼルスカブ | A biological surface acoustic wave (SAW) resonator amplification to detect a target analyte |
EP1949894B1 (en) * | 2007-01-25 | 2016-06-29 | Roche Diagnostics GmbH | Enhancement of vanadium-containing phosphatase inhibitors by polyols |
US8008035B2 (en) * | 2007-01-25 | 2011-08-30 | Roche Diagnostics Operations, Inc. | Enhancement of vanadium-containing phosphatase inhibitors |
Citations (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3905872A (en) | 1973-12-14 | 1975-09-16 | American Cyanamid Co | Alkaline phosphatase test material |
US3992158A (en) | 1973-08-16 | 1976-11-16 | Eastman Kodak Company | Integral analytical element |
US4089747A (en) | 1976-08-09 | 1978-05-16 | Eastman Kodak Company | Compositions for the detection of hydrogen peroxide |
US4258001A (en) | 1978-12-27 | 1981-03-24 | Eastman Kodak Company | Element, structure and method for the analysis or transport of liquids |
GB2064800A (en) | 1979-11-05 | 1981-06-17 | Fuji Photo Film Co Ltd | Photographic material |
US4292272A (en) | 1979-06-08 | 1981-09-29 | Fuji Photo Film Co., Ltd. | Multilayer analysis sheet for analyzing liquid samples |
EP0051183A1 (en) | 1980-10-15 | 1982-05-12 | Fuji Photo Film Co., Ltd. | Multilayer analysis element |
WO1982002601A1 (en) | 1981-01-23 | 1982-08-05 | Hospital Supply Corp American | Solid phase system for ligand assay |
EP0066648A1 (en) | 1981-06-05 | 1982-12-15 | Fuji Photo Film Co., Ltd. | Multilayer analysis element utilizing specific binding reaction |
JPS5845557A (en) | 1981-09-14 | 1983-03-16 | Yatoron:Kk | Reagent for quantitative determination of hydrogen peroxide |
US4430436A (en) | 1980-12-17 | 1984-02-07 | Konishiroku Photo Industry Co., Ltd. | Analytical element and method of use |
EP0122641A2 (en) | 1983-04-18 | 1984-10-24 | Fuji Photo Film Co., Ltd. | Analytical reagent, analytical method, and multilayer chemical-analytical element |
US4598044A (en) | 1983-02-11 | 1986-07-01 | National Research Development Corporation | Enhanced luminescent or luminometric assay |
WO1986007462A1 (en) | 1985-06-06 | 1986-12-18 | Amersham International Plc | Enzyme assay of body fluids |
US4670385A (en) | 1984-05-21 | 1987-06-02 | Eastman Kodak Company | Compositions and elements containing triarylmethane leuco dyes and methods using same |
US4670381A (en) | 1985-07-19 | 1987-06-02 | Eastman Kodak Company | Heterogeneous immunoassay utilizing horizontal separation in an analytical element |
US4729950A (en) | 1984-08-07 | 1988-03-08 | National Research Development Corporation | Enhanced luminescent or luminometric assay |
US4772553A (en) | 1982-08-03 | 1988-09-20 | Torii & Co., Inc. | Method for determination of enzyme activity |
US4828983A (en) | 1986-07-10 | 1989-05-09 | Eastman Kodak Company | Use of phenols and anilines to increase the rate of peroxidase catalyzed oxidation of leuco dyes |
US4828978A (en) | 1987-09-18 | 1989-05-09 | Eastman Kodak Company | Agglutination reagent and method of preparing same |
US4892833A (en) | 1982-07-07 | 1990-01-09 | Boehringer Mannheim Gmbh | Process and a reagent kit for the determination of direct and total filirubin |
US4892817A (en) | 1987-09-21 | 1990-01-09 | Biogenex Laboratories | Stable phosphatase substrate composition |
US4997772A (en) | 1987-09-18 | 1991-03-05 | Eastman Kodak Company | Water-insoluble particle and immunoreactive reagent, analytical elements and methods of use |
US5106732A (en) | 1989-02-14 | 1992-04-21 | Takeda Chemical Industries, Ltd. | Method for enhancement of chemiluminescence |
US5147777A (en) | 1990-06-18 | 1992-09-15 | Eastman Kodak Company | Biologically active reagents prepared from carboxy-containing polymer, analytical element and methods of use |
US5162219A (en) | 1990-06-18 | 1992-11-10 | Eastman Kodak Company | Preparation of amine-enriched proteins having an increased isoelectric point |
EP0517338A2 (en) | 1991-06-07 | 1992-12-09 | Johnson & Johnson Clinical Diagnostics, Inc. | Analytical element coated by a gravure process |
EP0517327A2 (en) | 1991-06-07 | 1992-12-09 | Johnson & Johnson Clinical Diagnostics, Inc. | Immunoassay with labeled hapten analogues |
US5177023A (en) | 1987-08-03 | 1993-01-05 | Eastman Kodak Company | Water-insoluble reagent elements containing same and methods of use |
EP0587222A2 (en) | 1992-08-31 | 1994-03-16 | Johnson & Johnson Clinical Diagnostics, Inc. | Dry immunoassay elements with a separate absorbent layer |
EP0603954A2 (en) | 1992-12-22 | 1994-06-29 | Johnson & Johnson Clinical Diagnostics, Inc. | Analytical element and immunoassay using a 4-hydroxy or 4-alkoxyarylacetamide as stabilizer |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4376165A (en) * | 1978-06-22 | 1983-03-08 | Miles Laboratories, Inc. | Method of preparing an enzyme-labeled ligand for use in specific binding assays and the labeled conjugate produced thereby |
-
1995
- 1995-07-11 AU AU24926/95A patent/AU697785B2/en not_active Expired
- 1995-07-17 CA CA002154013A patent/CA2154013C/en not_active Expired - Lifetime
- 1995-07-18 EP EP95305007A patent/EP0693552B1/en not_active Expired - Lifetime
- 1995-07-18 AT AT95305007T patent/ATE236246T1/en not_active IP Right Cessation
- 1995-07-18 JP JP18166395A patent/JP3715348B2/en not_active Expired - Lifetime
- 1995-07-18 DE DE69530148T patent/DE69530148T2/en not_active Expired - Lifetime
- 1995-10-10 US US08/541,864 patent/US5776714A/en not_active Expired - Lifetime
Patent Citations (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3992158A (en) | 1973-08-16 | 1976-11-16 | Eastman Kodak Company | Integral analytical element |
US3905872A (en) | 1973-12-14 | 1975-09-16 | American Cyanamid Co | Alkaline phosphatase test material |
US4089747A (en) | 1976-08-09 | 1978-05-16 | Eastman Kodak Company | Compositions for the detection of hydrogen peroxide |
US4258001A (en) | 1978-12-27 | 1981-03-24 | Eastman Kodak Company | Element, structure and method for the analysis or transport of liquids |
US4292272A (en) | 1979-06-08 | 1981-09-29 | Fuji Photo Film Co., Ltd. | Multilayer analysis sheet for analyzing liquid samples |
GB2064800A (en) | 1979-11-05 | 1981-06-17 | Fuji Photo Film Co Ltd | Photographic material |
EP0051183A1 (en) | 1980-10-15 | 1982-05-12 | Fuji Photo Film Co., Ltd. | Multilayer analysis element |
US4430436A (en) | 1980-12-17 | 1984-02-07 | Konishiroku Photo Industry Co., Ltd. | Analytical element and method of use |
WO1982002601A1 (en) | 1981-01-23 | 1982-08-05 | Hospital Supply Corp American | Solid phase system for ligand assay |
EP0066648A1 (en) | 1981-06-05 | 1982-12-15 | Fuji Photo Film Co., Ltd. | Multilayer analysis element utilizing specific binding reaction |
JPS5845557A (en) | 1981-09-14 | 1983-03-16 | Yatoron:Kk | Reagent for quantitative determination of hydrogen peroxide |
US4892833A (en) | 1982-07-07 | 1990-01-09 | Boehringer Mannheim Gmbh | Process and a reagent kit for the determination of direct and total filirubin |
US4772553A (en) | 1982-08-03 | 1988-09-20 | Torii & Co., Inc. | Method for determination of enzyme activity |
US4598044A (en) | 1983-02-11 | 1986-07-01 | National Research Development Corporation | Enhanced luminescent or luminometric assay |
EP0122641A2 (en) | 1983-04-18 | 1984-10-24 | Fuji Photo Film Co., Ltd. | Analytical reagent, analytical method, and multilayer chemical-analytical element |
US4670385A (en) | 1984-05-21 | 1987-06-02 | Eastman Kodak Company | Compositions and elements containing triarylmethane leuco dyes and methods using same |
US4729950A (en) | 1984-08-07 | 1988-03-08 | National Research Development Corporation | Enhanced luminescent or luminometric assay |
WO1986007462A1 (en) | 1985-06-06 | 1986-12-18 | Amersham International Plc | Enzyme assay of body fluids |
US4670381A (en) | 1985-07-19 | 1987-06-02 | Eastman Kodak Company | Heterogeneous immunoassay utilizing horizontal separation in an analytical element |
US4828983A (en) | 1986-07-10 | 1989-05-09 | Eastman Kodak Company | Use of phenols and anilines to increase the rate of peroxidase catalyzed oxidation of leuco dyes |
US5177023A (en) | 1987-08-03 | 1993-01-05 | Eastman Kodak Company | Water-insoluble reagent elements containing same and methods of use |
US4997772A (en) | 1987-09-18 | 1991-03-05 | Eastman Kodak Company | Water-insoluble particle and immunoreactive reagent, analytical elements and methods of use |
US4828978A (en) | 1987-09-18 | 1989-05-09 | Eastman Kodak Company | Agglutination reagent and method of preparing same |
US4892817A (en) | 1987-09-21 | 1990-01-09 | Biogenex Laboratories | Stable phosphatase substrate composition |
US5106732A (en) | 1989-02-14 | 1992-04-21 | Takeda Chemical Industries, Ltd. | Method for enhancement of chemiluminescence |
US5147777A (en) | 1990-06-18 | 1992-09-15 | Eastman Kodak Company | Biologically active reagents prepared from carboxy-containing polymer, analytical element and methods of use |
US5162219A (en) | 1990-06-18 | 1992-11-10 | Eastman Kodak Company | Preparation of amine-enriched proteins having an increased isoelectric point |
EP0517338A2 (en) | 1991-06-07 | 1992-12-09 | Johnson & Johnson Clinical Diagnostics, Inc. | Analytical element coated by a gravure process |
EP0517327A2 (en) | 1991-06-07 | 1992-12-09 | Johnson & Johnson Clinical Diagnostics, Inc. | Immunoassay with labeled hapten analogues |
EP0587222A2 (en) | 1992-08-31 | 1994-03-16 | Johnson & Johnson Clinical Diagnostics, Inc. | Dry immunoassay elements with a separate absorbent layer |
EP0603954A2 (en) | 1992-12-22 | 1994-06-29 | Johnson & Johnson Clinical Diagnostics, Inc. | Analytical element and immunoassay using a 4-hydroxy or 4-alkoxyarylacetamide as stabilizer |
Non-Patent Citations (2)
Title |
---|
GUNDERMANN AND MCCAPRA: "Chemiluminescence in Organic Chemistry", 1987, SPRINGER-VERLAG, BERLIN, pages: 204 - 207 |
YOSHITAKE ET AL, EUR. J. BIOCHEM., vol. 101, 1979, pages 395 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998002570A1 (en) * | 1996-07-15 | 1998-01-22 | Roche Diagnostics Gmbh | Blood substitute suppression by peroxides |
US6013467A (en) * | 1996-07-15 | 2000-01-11 | Boehringer Mannheim Gmbh | Blood substitute suppression by peroxides |
EP0977034A2 (en) * | 1998-07-27 | 2000-02-02 | Bayer Corporation | Transparent flow through membrane for dry reagent analytical devices |
EP0977034A3 (en) * | 1998-07-27 | 2000-02-23 | Bayer Corporation | Transparent flow through membrane for dry reagent analytical devices |
EP1307741A1 (en) * | 2000-07-26 | 2003-05-07 | Biodiagnostics, Inc. | Method for diagnosing thyroid conditions and for monitoring thyroxine therapy |
EP1307741A4 (en) * | 2000-07-26 | 2005-11-23 | Biodiagnostics Inc | Method for diagnosing thyroid conditions and for monitoring thyroxine therapy |
CN111518780A (en) * | 2020-06-04 | 2020-08-11 | 郑州伊美诺生物技术有限公司 | Preparation method of apo-horseradish peroxidase |
Also Published As
Publication number | Publication date |
---|---|
JPH08170961A (en) | 1996-07-02 |
CA2154013C (en) | 2006-12-19 |
US5776714A (en) | 1998-07-07 |
ATE236246T1 (en) | 2003-04-15 |
AU697785B2 (en) | 1998-10-15 |
CA2154013A1 (en) | 1996-01-20 |
DE69530148D1 (en) | 2003-05-08 |
AU2492695A (en) | 1996-02-01 |
JP3715348B2 (en) | 2005-11-09 |
EP0693552A3 (en) | 1996-04-03 |
EP0693552B1 (en) | 2003-04-02 |
DE69530148T2 (en) | 2004-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4828983A (en) | Use of phenols and anilines to increase the rate of peroxidase catalyzed oxidation of leuco dyes | |
EP0321261B1 (en) | Use of immobilized biotinylated receptor in test device, kit and method for determining a ligand | |
JPS61292060A (en) | Analyzing element | |
US5155024A (en) | Binder composition and analytical element having stabilized peroxidase in layer containing the composition | |
EP0693552B1 (en) | Analytical element, composition and method using modified apo-horseradish peroxidase | |
US4874692A (en) | Binder composition and analytical element having stabilized peroxidase in layer containing the composition | |
JPS62100660A (en) | Immunoassay method of high molecule | |
EP0603954B1 (en) | Immunoassay using a 4-hydroxy or 4-alkoxyarylacetamide as stabilizer | |
EP0848819B1 (en) | Analytical element and method for the determination of a specific binding ligand using a vanadium bromoperoxidase as a signal-generating enzyme | |
CA2028175A1 (en) | Buffered wash composition, insolubilizing composition, test kits and method of use | |
US5696193A (en) | Immunoassay elements comprising polymers containing vandium IV (V+4) ions | |
EP0687910B1 (en) | Test kit and method for competitive specific binding assay | |
EP0517338B1 (en) | Analytical element coated by a gravure process | |
EP0603962B1 (en) | Immunoassay elements having a separate receptor layer | |
US5565326A (en) | Separation-free specific binding assays using anti-inhibitor antibodies | |
Rubtsova et al. | Chemiluminescent immunoassay: Application of a portable scanning luminometer for the determination of 2, 4‐dichlorophenoxyacetic acid in microtiter and membrane strip format | |
EP0184701B1 (en) | A method for determining a ligand | |
EP0740157A2 (en) | Immunoassay element comprising both labeled ligand and receptors | |
JP3727661B6 (en) | Analytical elements and methods for determination of specific binding ligands using vanadium bromoperoxidase as a signal generating enzyme | |
CA2093103A1 (en) | Chemiluminescent signal generating reagent composition containing an azide, test kit and immunoassay using same | |
JPS62247258A (en) | Analysis element | |
JPH0588784B2 (en) | ||
JPH04164254A (en) | Immunological multilayer analyzing element and analyzing method | |
JPS63131062A (en) | Immunological analysis element |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK FR GB IT LI NL SE |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK FR GB IT LI NL SE |
|
17P | Request for examination filed |
Effective date: 19960906 |
|
17Q | First examination report despatched |
Effective date: 20010119 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH DE DK FR GB IT LI NL SE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030402 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030402 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030402 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REF | Corresponds to: |
Ref document number: 69530148 Country of ref document: DE Date of ref document: 20030508 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: DR. LUSUARDI AG |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030702 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030702 |
|
NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
ET | Fr: translation filed | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20040105 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Owner name: JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. Free format text: JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC.#100 INDIGO CREEK DRIVE#ROCHESTER, NEW YORK 14650-0880 (US) -TRANSFER TO- JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC.#100 INDIGO CREEK DRIVE#ROCHESTER, NEW YORK 14650-0880 (US) |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20140714 Year of fee payment: 20 Ref country code: DE Payment date: 20140716 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20140708 Year of fee payment: 20 Ref country code: GB Payment date: 20140716 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20140714 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 69530148 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20150717 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20150717 |